F8 and hemophilia A: Emicizumab (EMI), a bispecific monoclonal antibody that mimics the function of activated factor (F)VIII and is not recognized by anti-FVIII antibodies, has established itself as the prophylactic treatment of choice for people with hemophilia A, both with and without persistent inhibitors [[1], [2], [3]].